查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553702

阿黴素市場規模、佔有率、趨勢分析報告：按劑型、按應用、按分銷管道、按地區、細分市場預測，2024-2030

Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

阿黴素市場成長和趨勢：

Grand View Research最新報告顯示，到2030年，全球阿黴素市場規模預計將達到15.3億美元，預測期內複合年成長率為6.6%。

越來越多的參與者進入市場以遏制藥物短缺，這是預計未來幾年推動市場的關鍵因素之一。阿黴素的製造商包括 Ortho Biotech Products, LP、Ben Venue Laboratories, Inc. 和 Bristol-Myers Squibb Company。對阿黴素的需求是由其在各種應用中不斷增加的適應症所推動的，包括愛滋病相關的卡波西氏肉瘤、多發性骨髓瘤、神經母細胞瘤、骨癌和卵巢癌。克服不良健康影響的藥物配方技術進步以及奈米顆粒和脂質體塗層等各種類型的藥物傳輸系統的引入是推動該行業成長的一些關鍵因素。

美國政府發布行政命令，解決美國救生藥物、化療藥物和急需藥物的短缺問題。根據監測、流行病學和最終結果 (SEER) 估計，2016 年惡性患者的預期數量為：-

  • 白血病 60,140 人
  • 乳癌 2,46,660 人
  • 60,050 人患有子宮內膜癌
  • 胃癌 26,370 人
  • 肝癌：39,230 人
  • 腎癌：62,700 人

根據白血病和淋巴瘤協會2016年的估計，預計約有60,140人被診斷出患有白血病。盛行率的增加和隨後生存率的增加是技術進步和新治療方法越來越多採用的因素之一。

阿黴素市場報告亮點

  • 2023年，阿黴素市場最大的應用將是乳癌。該藥物與Cisplatin聯合治療的需求不斷成長是預計推動阿黴素市場的關鍵因素之一。
  • 在預測期內，膀胱癌領域預計將以顯著的複合年成長率成長。阿黴素是晚期膀胱癌的標準治療方法，仍然是該疾病治療的重要組成部分。
  • 2023年，北美佔據全球阿黴素市場的大部分，市場佔有率超過37.7%。強生公司和太陽製藥工業有限公司等強大市場參與者的存在以及對有效藥物替代品的認知不斷提高是該地區高市場佔有率的主要因素。
  • 亞太地區是該市場成長最快的地區。中國、日本和印度等國家抗癌藥物治療需求未滿足以及製藥業快速成長是預計未來幾年推動市場發展的因素之一。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章阿黴素市場變數、趨勢和範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 阿黴素市場分析工具
    • 波特的分析
    • PESTEL分析

第4章阿黴素市場：按劑型的估計和趨勢分析

  • 細分儀表板
  • 阿黴素市場：2023 年和 2030 年劑型變化分析
  • 凍乾粉
  • 阿黴素注射液

第5章阿黴素市場：按應用估計和趨勢分析

  • 細分儀表板
  • 阿黴素市場：應用分析，2023 年和 2030 年
  • 膀胱癌
  • 卡波西氏肉瘤
  • 白血病
  • 淋巴瘤
  • 其他

第6章阿黴素市場：按分銷管道估算和趨勢分析

  • 細分儀表板
  • 阿黴素市場：2023 年和 2030 年分銷通路變化分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章阿黴素市場：區域估計和趨勢分析

  • 2023 年及 2030 年阿黴素市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Sun Pharmaceutical Industries Ltd
    • Cipla.
    • Cadila Pharmaceuticals.
    • Novartis AG
    • Dr. Reddy's Laboratories Ltd.
    • SRS Life Sciences
    • MicroBiopharm Japan Co., Ltd.
    • Baxter
簡介目錄
Product Code: GVR-1-68038-288-4

Doxorubicin Market Growth & Trends:

The global doxorubicin market size is expected to reach USD 1.53 billion by 2030, registering a CAGR of 6.6% during the forecast period, according to a new report by Grand View Research, Inc. The growing number of players in the market to control the shortage of the drug is one of the crucial factors that is expected to drive the market in the coming few years. Some of the doxorubicin manufacturers are Ortho Biotech Products, LP, Ben Venue Laboratories, Inc., and Bristol-Myers Squibb Company. The increasing indication of doxorubicin drug in various applications such as AIDS related Kaposi Sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand for the drug. The technological advancement in the drug formulations to overcome the adverse effects on health and also introduces various types of drug delivery systems such as nanoparticles or liposomal coated are some of the pivotal factors that are impelling the industry growth.

The U.S. government had issued an executive order to overcome the shortage of life saving drugs, chemotherapy agents, and critically needed drugs in the U.S. region, is one of the indicators accounted for the increasing number of players in this sector. Based on the estimates of Surveillance, Epidemiology, and End Results (SEER), the anticipated number of malignancy cases in 2016 are listed below: -

  • Leukemia 60,140
  • Breast cancer 2,46,660
  • Endometrial cancer 60,050
  • Gastric cancer 26,370
  • Liver cancer 39,230
  • Kidney Cancer 62,700

According to the estimates of the Leukemia & Lymphoma Society in 2016, about 60,140 people are anticipated to be diagnosed with leukemia. The growing prevalence and subsequently increasing survival is one of the factors that indicates the technological advancement and growing adoption of new treatment procedures.

Doxorubicin Market Report Highlights:

  • In 2023, breast cancer is the largest application of doxorubicin market. The growing demand for the drug in combination therapy with cisplatin is one of the pivotal factors that are expected to impel the doxorubicin market.
  • Bladder cancer segment projected to grow at a significant CAGR during the forecast period. Doxorubicin, which has been a standard treatment for advanced bladder cancer, remains a critical component in the management of the disease.
  • In 2023, North America held majority of market share of over 37.7% in the global doxorubicin market. The presence of dominating market players such as Johnson & Johnson and Sun Pharmaceuticals Industries Ltd. and rising awareness regarding efficacious drug alternatives are few of the key factors attributed to the regions high market share.
  • Asia Pacific is the fastest growing region in this market. The presence of unmet demand for anti-cancer treatment and rapidly growing pharmaceutical industries in countries such as China, Japan, and India are among some factors that are expected to drive the market in the coming few years.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Doxorubicin Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Doxorubicin Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Doxorubicin Market: Drug Formulation Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Doxorubicin Market: Drug Formulation Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Lyophilized Powder
    • 4.3.1. Lyophilized Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Doxorubicin Injection
    • 4.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Doxorubicin Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Doxorubicin Market: Application Analysis, 2023 & 2030 (USD Million)
  • 5.3. Bladder Cancer
    • 5.3.1. Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Kaposi Sarcoma
    • 5.4.1. Kaposi Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Leukemia
    • 5.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Lymphoma
    • 5.6.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Doxorubicin Market: Regional Estimates & Trend Analysis

  • 7.1. Doxorubicin Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Spain Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific
    • 7.4.2. Asia Pacific Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. India
      • 7.4.5.1. India Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Australia
      • 7.4.7.1. Australia Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Thailand
      • 7.4.8.1. Thailand Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Johnson & Johnson Services, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sun Pharmaceutical Industries Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Cipla.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Cadila Pharmaceuticals.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Dr. Reddy's Laboratories Ltd.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. SRS Life Sciences
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. MicroBiopharm Japan Co., Ltd.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Baxter
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives